Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing
Market News Market Pulse Stocks News ETF News Crypto News

AC Immune SA

Contributing Author

Recent Articles by AC Immune SA

Aug-20
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 ACIU GlobeNewswire
Aug-11
AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson's Disease (PD) ACIU +11.40% GlobeNewswire
Aug-05
AC Immune First Half 2026 Financial and Corporate Update ACIU GlobeNewswire
Jul-07
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC 2026 ACIU GlobeNewswire
Jun-30
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease ACIU -10.53% GlobeNewswire
Jun-11
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease ACIU +6.60% GlobeNewswire
May-22
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS ACIU GlobeNewswire
May-12
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM ACIU GlobeNewswire
Apr-30
AC Immune First Quarter 2026 Financial and Corporate Updates ACIU GlobeNewswire
Apr-30
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease ACIU GlobeNewswire
Apr-07
AC Immune Announces Amendment to Morphomer Tau License and Collaboration Agreement with Lilly ACIU +15.19% GlobeNewswire
Mar-19
AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026 ACIU GlobeNewswire
Mar-13
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update ACIU GlobeNewswire
Mar-05
AC Immune Announces Upcoming Industry Symposium on Parkinson's Disease and Presentation at AD/PD 2026 ACIU GlobeNewswire
Feb-24
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor ACIU +7.51% GlobeNewswire
Dec-11
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease ACIU +15.41% GlobeNewswire
Nov-11
AC Immune to Present at the Jefferies 2025 London Healthcare Conference ACIU GlobeNewswire
Nov-04
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update ACIU GlobeNewswire
Oct-28
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board ACIU GlobeNewswire
Oct-24
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine ACIU +15.66% GlobeNewswire
Sep-25
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine ACIU +6.59% GlobeNewswire
Sep-04
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway ACIU GlobeNewswire
Aug-05
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update ACIU +11.62% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)